Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Aurobindo Pharma Limited (NSE: AUROPHARMA), ISIN INE406A01037 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
AUROPHARMA last traded at ₹1725.00 (+1.65%), with a 52-week range of ₹1066.00 to ₹1739.00 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 51.88%, FIIs 16.38%, DIIs 25.10%, mutual funds 16.71%.
EquiSense Score (ECS): 84/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.